bioMerieux' profits up 18% thanks to international sales
This article was originally published in Clinica
Executive Summary
Profits at French diagnostics company bioMerieux rose 18% in 1995 compared with the year before to Fr 139 million ($27.8 million). Sales volume increased 6% over the year, but weakness in the US dollar and several European currencies meant revenues rose just 2.1% to Fr 2,461 million in fiscal 1995 in what president Alain Merieux termed a difficult economic environment.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.